Search This Blog

Tuesday, November 5, 2024

DA Bragg held in contempt for not turning over files in sweetheart plea from doc

 Manhattan’s district attorney was held in contempt by a state court for refusing to turn over plea deal documents with a doctor who was later convicted as a sexual predator.

DA Alvin Bragg’s office must now comply with the subpoena to produce documents related to 2014 criminal action against perv Dr. Robert Hadden, Judge Richard G. Latin ruled last month.

Hadden (center), 64, was convicted in January 2023 following a Manhattan federal trial on all four counts of enticing women to travel across state lines so he could abuse them.Steven Hirsch

Attorney Anthony DiPietro, who is representing hundreds of Hadden’s victims in the civil suit, is also seeking the DA’s communications with Hadden’s longtime employer, Columbia University, in relation to Hadden’s 2016 no-jail plea deal with Bragg’s predecessor, former DA Cyrus Vance Jr.

The deal was struck despite Hadden admitting to sexually abusing six female patients during his long tenure as a gynecologist at the university.

00:00
04:13

As part of the deal, the DA agreed not to prosecute him for any similar crimes that happened before Feb. 22 2016, The Post reported at the time.

Federal prosecutors also noticed what they called a “deliberate” attempt to hide documents related to the deal during their own trial in 2020.

“They should be prosecuting Columbia [University], not protecting them,” said DiPietro, who said he’s already resolved cases, winning more than $250 million for over 230 clients.

The DA’s office could face a slew of penalties if it blows past a fast-approaching deadline. 

Manhattan District Attorney Alvin Bragg was found in contempt of court for refusing to comply with several subpoenas regarding his predecessor’s criminal action against Dr. Robert Hadden, which ended with a no-jail plea deal.Steven Hirsch

The current case, filed in 2022 in Manhattan Supreme Court, includes nearly 550 clients, and DiPietro estimates the liability could top an eye-watering $1 billion due to Hadden’s sexual abuse and, what he says is a Columbia coverup.

Hadden was convicted by federal prosecutors of sex trafficking in 2023 and was sentenced to 20 years in prison. Victims recounted that the sick doctor would make oral and other sexual contact with them during what were supposed to be routine medical appointments.

DiPietro said he’s seeking these documents relating to the DA’s criminal case and plea deal because it could undercut the claim he says Columbia has made from the beginning — that they had no idea Hadden was routinely sexually abusing his patients.

Robert Hadden took a plea deal during his prosecution by the Manhattan DA’s office in 2016 and saw no jail time, despite admitting to abusing at least six patients.Steven Hirsch

“I grew up understanding that covering up a crime is a separate crime itself,” he told The Post. “And now it seems like the district attorney is helping Columbia hide those documents, and we want the documents.”

Documents related to the sweetheart plea deal — which only forced Hadden to forfeit his medical license and register as a level one sex offender — could help establish what Columbia knew and when they knew it, the attorney said.

“If the lawyers at the District Attorney’s office — the prosecutors — are worth their salt, they’re gonna get this information before they offer any plea deal,” DiPietro said.

In court filings, the DA’s office argues against complying with the multiple subpoenas, claiming technical issues and that the documents are protected as both privileged work-products and grand jury materials.

Columbia officials declined to comment on pending litigation. 

A spokesperson for the DA said the office has concerns over the confidentiality of victims and that its reason for withholding documents will be based on the law.

Earlier this year, a judge agreed with DiPietro that Columbia was sending “catch and kill” letters to Hadden’s victims — forcing them to sign non-disclosure agreements in order to claim part of their “woefully inadequate” $100 million survivors fund.

The judge hit the university with a restraining order, forbidding them to contact any of the survivors going forward.

https://nypost.com/2024/11/05/us-news/da-bragg-held-in-contempt-for-not-turning-over-docs-in-sweetheart-plea-deal-with-sicko-doctor/

'Google fixes ‘where to vote’ issue in Harris, Vance searches'

 Google said Tuesday it fixed an error that was causing a “where to vote” panel to appear when searching for Vice President Harris and Sen. JD Vance (R-Ohio). 

The search giant said the panel was triggered for certain searches, such as “where to vote for Harris” or “where to vote for Vance,” because Harris and Vance are also both names of U.S. counties. 

“Note very few people actually search for voting places this way,” Google wrote in a post on the social platform X. 

It also responded to Elon Musk, who highlighted another X user’s post about the issue that suggested it reflected a bias against former President Trump. 

“Google shows a ‘Where to Vote’ section with a map for Kamala Harris, but not for Donald Trump,” the user wrote. “Google is the biggest corporate donor to the Democratic Party.” 

Google explained the county name issue in its response to Musk and noted that a fix was coming.  

Republicans, including Trump, have previously accused of Google of favoring Democrats.  

Earlier this year, the former president threatened to prosecute the tech giant if elected, alleging the search engine was “only” showing “bad” stories about him and “good” articles about Harris. 

“This is an ILLEGAL ACTIVITY, and hopefully the Justice Department will criminally prosecute them for this blatant Interference of Elections,” Trump wrote in a post on Truth Social in September. 

“If not, and subject to the Laws of our Country, I will request their prosecution, at the maximum levels, when I win the Election, and become President of the United States!” he added. 

Trump’s comments appeared to come in response to a report from a conservative media watchdog group, which alleged Google “pads its search results” with articles from legacy news outlets that appear above candidates’ campaign websites. 

Google noted in a statement at the time that campaign websites for both Harris and Trump “consistently appear at the top of Search for relevant and common search queries.” 

https://thehill.com/policy/technology/4973585-google-fixes-voting-panel-error/

Rhythm Q3, update

 -- Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million --

-- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program --

-- Top-line data readout for Phase 3 trial evaluating setmelanotide in 120 patients with acquired hypothalamic obesity on track for 1H 2025 --

-- sNDA to expand IMCIVREE label to include patients as young as 2 years old in approved indications accepted by FDA for Priority Review with PDUFA goal date of Dec. 26, 2024 --

-- Cash on-hand expected to support planned operations into 2026 --

-- Management to host conference call today at 5:00 p.m. ET --

Conference Call Information
Rhythm Pharmaceuticals will host a live conference call and webcast at 5:00 p.m. ET today to review its third quarter 2024 financial results and recent business activities. Participants may register for the conference call here. It is recommended that participants join the call ten minutes prior to the scheduled start.

A webcast of the call will also be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/. The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the conference call and will be available for 30 days following the call.

https://www.globenewswire.com/news-release/2024/11/05/2975189/0/en/Rhythm-Pharmaceuticals-Reports-Third-Quarter-2024-Financial-Results-and-Business-Update.html

Ultragenyx backs guidance after Q3

 Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million

Reaffirmed 2024 expected total revenue guidance of $530 million to $550 million

Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta

DTX401 Phase 3 follow-up data demonstrated higher and faster 62% mean reduction in cornstarch in crossover patients with glycogen storage disease type Ia (GSDIa)

2024 Financial Guidance
For the full year 2024, the company expects:

  • Total revenue to be in the range of $530 million to $550 million
  • Crysvita revenue to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.
  • Dojolvi revenue to be in the range of $75 million to $80 million
  • Net Cash Used in Operations of around $400 million
Conference Call and Webcast Information
Ultragenyx will host a conference call today, Tuesday, November 5, 2024, at 2 p.m. PT/5 p.m. ET to discuss the third quarter 2024 financial results and provide a corporate update. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for one year.

Syndax Q3, update

 –  New revumenib and Niktimvo clinical data will be highlighted at 66th ASH Annual Meeting –

– mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 –

– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –

– Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg –

–  $350 million royalty funding agreement for Niktimvo expected to fund Company through profitability –

– Company to host a conference call today at 4:30 p.m. ET –

Financial Guidance

For the full year of 2024, the Company expects research and development expenses to be $245 to $250 million (prior guidance $240 million to $260 million) and total operating expenses to be $365 to $370 million (prior guidance $355 million to $375 million), which includes milestone payments that the Company expects to become due as well as an estimated $41 million (prior guidance $43 million) in non-cash stock compensation expense.

Syndax expects that its cash, cash equivalents and marketable securities, together with the $350 million from the sale of a portion of the Niktimvo royalty and anticipated product revenue and interest income, enables the company to reach profitability. 

Conference Call and Webcast

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET today, Tuesday, November 5, 2024.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax3Q24
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX3Q24.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

https://www.prnewswire.com/news-releases/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update-302296867.html